Financials in USD. Standardized financial statements.
A compact view of how Alterity Therapeutics Limited turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $5.44M | $4.02M | $3.92M | $5.12M | $4.34M | $0 | $108,538 | $201,174 | $132,396 | $142,657 |
| Revenue Growth? | +35.3% | +2.6% | -23.6% | +18.1% | 0.0% | -100.0% | -46.0% | +51.9% | -7.2% | 0.0% |
| Cost of Revenue? | $127,523 | $214,304 | $285,067 | $364,665 | $360,026 | $112,427 | $29,696 | $21,799 | $21,328 | $22,810 |
| Gross Profit? | $5.31M | $3.80M | $3.63M | $4.76M | $3.98M | -$112,427 | $78,842 | $179,375 | $111,068 | $119,847 |
| Gross Margin? | +97.7% | +94.7% | +92.7% | +92.9% | +91.7% | 0.0% | +72.6% | +89.2% | +83.9% | +84.0% |
| Operating Expenses? | $19.89M | $23.41M | $18.24M | $20.26M | $19.16M | $10.07M | $12.47M | $11.10M | $6.77M | $8.49M |
| Operating Income? | -$14.57M | -$19.60M | -$14.64M | -$15.50M | -$15.18M | -$10.41M | -$12.71M | -$7.77M | -$6.88M | -$8.59M |
| EBITDA? | -$14.63M | -$19.57M | -$14.60M | -$17.39M | -$15.16M | -$13.34M | -$12.77M | -$11.37M | -$6.86M | -$8.56M |
| Income Before Tax | -$12.08M | -$19.08M | -$13.70M | -$12.78M | -$15.31M | -$10.06M | -$12.34M | -$8.27M | -$7.54M | -$7.73M |
| Income Tax Expense | $68,055 | $46,088 | $104,459 | $70,008 | $0 | -$362,188 | -$376,031 | -$495,440 | $660,213 | $0 |
| Net Income? | -$12.15M | -$19.12M | -$13.81M | -$12.85M | -$15.31M | -$10.06M | -$11.96M | -$8.27M | -$7.54M | -$7.73M |
| EPS? | $-1.14 | $-3.12 | $-3.42 | $-3.18 | $-5.40 | $-6.48 | $-11.64 | $-9.30 | $-8.46 | $-8.70 |
| Diluted EPS? | $-1.14 | $-3.12 | $-3.42 | $-3.18 | $-5.40 | $-6.48 | $-11.64 | $-9.30 | $-8.46 | $-8.70 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality